Receptor, Angiotensin, Type 1
"Receptor, Angiotensin, Type 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An angiotensin receptor subtype that is expressed at high levels in a variety of adult tissues including the CARDIOVASCULAR SYSTEM, the KIDNEY, the ENDOCRINE SYSTEM and the NERVOUS SYSTEM. Activation of the type 1 angiotensin receptor causes VASOCONSTRICTION and sodium retention.
| Descriptor ID |
D044140
|
| MeSH Number(s) |
D12.776.543.750.695.047.625 D12.776.543.750.750.130.750
|
| Concept/Terms |
Receptor, Angiotensin, Type 1- Receptor, Angiotensin, Type 1
- Angiotensin II Type 1 Receptor
- Angiotensin AT1 Receptor
- AT1 Receptor, Angiotensin
- Receptor, Angiotensin AT1
- Angiotensin Type 1 Receptor
- Receptor, Angiotensin II Type 1
Receptor, Angiotensin, Type 1b- Receptor, Angiotensin, Type 1b
- Angiotensin II Type 1b Receptor
- Angiotensin Type 1b Receptor
- Angiotensin AT1b Receptor
- AT1b Receptor, Angiotensin
- Receptor, Angiotensin AT1b
- Receptor, Angiotensin II Type 1b
Receptor, Angiotensin, Type 1a- Receptor, Angiotensin, Type 1a
- Angiotensin II Type 1a Receptor
- Angiotensin AT1a Receptor
- AT1a Receptor, Angiotensin
- Receptor, Angiotensin AT1a
- Angiotensin Type 1a Receptor
- Receptor, Angiotensin II Type 1a
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Angiotensin, Type 1".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Angiotensin [D12.776.543.750.695.047]
- Receptor, Angiotensin, Type 1 [D12.776.543.750.695.047.625]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Angiotensin [D12.776.543.750.750.130]
- Receptor, Angiotensin, Type 1 [D12.776.543.750.750.130.750]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Angiotensin, Type 1".
This graph shows the total number of publications written about "Receptor, Angiotensin, Type 1" by people in this website by year, and whether "Receptor, Angiotensin, Type 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 5 | 5 |
| 2018 | 3 | 1 | 4 |
| 2020 | 0 | 6 | 6 |
| 2021 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, Angiotensin, Type 1" by people in Profiles.
-
Resveratrol supplementation reduces ACE2 expression in human adipose tissue. Adipocyte. 2021 12; 10(1):408-411.
-
Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One. 2021; 16(9):e0257016.
-
Neurological effects of elevated levels of angiotensin II in COVID-19 patients. Hum Cell. 2021 Nov; 34(6):1941-1942.
-
Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers-Relevance to COVID-19. Biomolecules. 2021 07 03; 11(7).
-
Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J Autoimmun. 2021 08; 122:102683.
-
Identification of oligopeptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) non structural protein 8 (NSP8) and their similarities with type 1 angiotensin II receptor key sites. Biomed Pharmacother. 2021 Sep; 141:111722.
-
Dysregulation of COVID-19 related gene expression in the COPD lung. Respir Res. 2021 May 29; 22(1):164.
-
Is nutraceutical supplementation appropriate for COVID-19 management? Allergy Asthma Proc. 2021 05 01; 42(3):e103-e105.
-
IL-6 Induction and Signaling: Horizons of COVID-19-Related Pathogenesis. DNA Cell Biol. 2021 May; 40(5):639-642.
-
In silico Nigellidine (N. sativa) bind to viral spike/active-sites of ACE1/2, AT1/2 to prevent COVID-19 induced vaso-tumult/vascular-damage/comorbidity. Vascul Pharmacol. 2021 06; 138:106856.